Review Article

肛周瘘管克罗恩病(CD)的内科-外科综合疗法:一起做

卷 20, 期 13, 2019

页: [1373 - 1383] 页: 11

弟呕挨: 10.2174/1389450120666190520103454

价格: $65

Open Access Journals Promotions 2
摘要

瘘管性肛周克罗恩病(pCD)是一种侵略性表型,患者不仅患有肛周表现,而且其腔内疾病的病程也在恶化。 本文介绍了临床医生在处理pCD患者时需要考虑的6个关键步骤,其中包括: (i)确保迅速诊断,(ii)多学科管理,(iii)心理支持,(iv)使用多模式药物和手术治疗策略,(v)持续监控和优化治疗,以及(vi)确保患者拥有 必要时获得护理的方式。 患有pCD瘘管的患者通常会出现无法预测的疾病进程,并且难以完全缓解。 因此,考虑到细微差别的方法对于使更广泛的多学科团队和患者参与所有决策至关重要。

关键词: 克罗恩病,肛周,手术,药物治疗,腔腔疾病,优化治疗。

图形摘要
[1]
Tarrant KM, Barclay ML, Frampton CMA, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103(12): 3082-93.
[http://dx.doi.org/10.1111/j.1572-0241.2008.02212.x] [PMID: 19086959]
[2]
Keighley MR, Allan RN. Current status and influence of operation on perianal Crohn’s disease. Int J Colorectal Dis 1986; 1(2): 104-7.
[http://dx.doi.org/10.1007/BF01648416] [PMID: 3611935]
[3]
Adegbola SO, Pisani A, Sahnan K, et al. Medical and surgical management of perianal Crohn’s disease. Ann Gastroenterol 2018; 31(2): 129-39.
[http://dx.doi.org/10.20524/aog.2018.0236] [PMID: 29507460]
[4]
Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn’s disease: future directions. Gut 2018; 67(6): 1181-94.
[http://dx.doi.org/10.1136/gutjnl-2017-314918] [PMID: 29331943]
[5]
Hellers G, Bergstrand O, Ewerth S, Holmström B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980; 21(6): 525-7.
[http://dx.doi.org/10.1136/gut.21.6.525] [PMID: 7429313]
[6]
Riss S, Schwameis K, Mittlböck M, et al. Sexual function and quality of life after surgical treatment for anal fistulas in Crohn’s disease. Tech Coloproctol 2013; 17(1): 89-94.
[http://dx.doi.org/10.1007/s10151-012-0890-x] [PMID: 22956209]
[7]
Adegbola S, Dibley L, Sahnan K, et al. N002 A qualitative exploration into experiences of living with Crohn’s anal fistula. J Crohn’s Colitis 2018; 12((supplement_1)): S568-9.
[http://dx.doi.org/10.1093/ecco-jcc/jjx180.1016]
[8]
Norton C, Dibley LB, Bassett P. Faecal incontinence in inflammatory bowel disease: associations and effect on quality of life. J Crohn’s Colitis 2013; 7(8): e302-11.
[http://dx.doi.org/10.1016/j.crohns.2012.11.004] [PMID: 23228710]
[9]
Kamiński JP, Zaghiyan K, Fleshner P. Increasing experience of ligation of the intersphincteric fistula tract for patients with Crohn’s disease: what have we learned? Colorectal Dis 2017; 19(8): 750-5.
[http://dx.doi.org/10.1111/codi.13668] [PMID: 28371062]
[10]
Adegbola SO, Sahnan K, Tozer PJ, et al. Symptom amelioration in Crohn’s perianal fistulas using video assisted anal fistula treatment (VAAFT). J Crohn’s Colitis 2018; (May): 1-6.
[http://dx.doi.org/10.1093/ecco-jcc/jjy071] [PMID: 29800373]
[11]
Sahnan K, Tozer PJ, Adegbola SO, et al. Developing a core outcome set for fistulising perianal Crohn’s disease. Gut 2018; 01136.
[http://dx.doi.org/doi:10.1136/gutjnl-2017-315503]
[12]
Singh S, Ding NS, Mathis KL, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn’s disease. Aliment Pharmacol Ther 2015; 42(7): 783-92.
[http://dx.doi.org/10.1111/apt.13356] [PMID: 26264359]
[13]
Sahnan K, Adegbola SO, Tozer PJ, Watfah J, Phillips RK. Perianal abscess. BMJ 2017; 356(8): j475.
[http://dx.doi.org/10.1136/bmj.j475] [PMID: 28223268]
[14]
Castaño-Milla C, Chaparro M, Saro C, et al. Effectiveness of adalimumab in perianal fistulas in crohn’s disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015; 49(1): 34-40.
[http://dx.doi.org/10.1097/MCG.0000000000000169] [PMID: 25485513]
[15]
Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum 2012; 55(7): 773-7.
[http://dx.doi.org/10.1097/DCR.0b013e31825228b0] [PMID: 22706129]
[16]
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J-P, Cosnes J. Predictors of Crohn’s disease. Gastroenterology 2006; 130(3): 650-6.
[http://dx.doi.org/10.1053/j.gastro.2005.12.019] [PMID: 16530505]
[17]
Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(3): 496-505.
[http://dx.doi.org/10.1002/ibd.21719] [PMID: 21509908]
[18]
Schoepfer AM, Dehlavi M-A, Fournier N, et al. Diagnostic delay in Crohn’s disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol 2013; 108(11): 1744-53.
[http://dx.doi.org/10.1038/ajg.2013.248] [PMID: 23978953]
[19]
D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: An open randomised trial. Lancet 2008; 371(9613): 660-7.
[http://dx.doi.org/10.1016/S0140-6736(08)60304-9] [PMID: 18295023]
[20]
Pearce L, Newton K, Smith SR, et al. Multicentre observational study of outcomes after drainage of acute perianal abscess. Br J Surg 2016; 103(8): 1063-8.
[http://dx.doi.org/10.1002/bjs.10154] [PMID: 27061287]
[21]
Sahnan K, Askari A, Adegbola SO, et al. Natural history of anorectal sepsis. Br J Surg 2017; 104(13): 1857-65.
[http://dx.doi.org/10.1002/bjs.10614] [PMID: 28857130]
[22]
Lee MJ, Heywood N, Sagar PM, Brown SR, Fearnhead NS. Surgical management of fistulating perianal Crohn’s disease: a UK survey. Colorectal Dis 2017; 19(3): 266-73.
[http://dx.doi.org/10.1111/codi.13462] [PMID: 27423057]
[23]
Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 2014; 63(9): 1381-92.
[http://dx.doi.org/10.1136/gutjnl-2013-306709] [PMID: 24951257]
[24]
Sahnan K, Adegbola SO, Tozer PJ, et al. Improving the understanding of perianal crohn fistula through 3d modeling. Ann Surg 2018; 267(6): e105-7.
[http://dx.doi.org/10.1097/SLA.0000000000002629] [PMID: 29232211]
[25]
Sahnan K, Adegbola SO, Tozer PJ, et al. Innovation in the imaging perianal fistula: a step towards personalised medicine. Therap Adv Gastroenterol 2018; 24(11): 1756284818775060.
[http://dx.doi.org/10.1177/1756284818775060] [PMID: 29854001]
[26]
Zhang CK, Hewett J, Hemming J, et al. The influence of depression on quality of life in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19(8): 1732-9.
[http://dx.doi.org/10.1097/MIB.0b013e318281f395] [PMID: 23669400]
[27]
Mahadev S, Young JM, Selby W, Solomon MJ. Self-reported depressive symptoms and suicidal feelings in perianal Crohn’s disease. Colorectal Dis 2012; 14(3): 331-5.
[http://dx.doi.org/10.1111/j.1463-1318.2011.02613.x] [PMID: 21689304]
[28]
Adegbola S, Dibley L, Sahnan K, et al. N001 Developing a quality of life score for Crohn’s anal fistula (CAF-QoL). J Crohn’s Colitis 2018; 12((supplement_1): S568-8.
[http://dx.doi.org/doi:10.1093/ecco-jcc/jjx180.1015]
[29]
Yassin N, Al-Hassi H, Ansari T, et al. PTU-200 Why do crohn’s and idiopathic anal fistulae persist? Gut 2015; 64((Suppl 1)): A151-1.
[http://dx.doi.org/10.1136/gutjnl-2015-309861.315]
[30]
Gionchetti P, Dignass A, Danese S, et al. 3rd European evidence-based consensus on the diagnosis and management of crohn’s disease 2016: part 2: surgical management and special situations. J Crohn’s Colitis 2017; 11(2): 135-49.
[http://dx.doi.org/10.1093/ecco-jcc/jjw169] [PMID: 27660342]
[31]
Kawalec P, Mikrut A, Wiśniewska N, Pilc A. Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn’s disease: systematic review and meta-analysis. Arch Med Sci 2013; 9(5): 765-79.
[http://dx.doi.org/10.5114/aoms.2013.38670] [PMID: 24273556]
[32]
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350(9): 876-85.
[http://dx.doi.org/10.1056/NEJMoa030815] [PMID: 14985485]
[33]
Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005; 128(4): 862-9.
[http://dx.doi.org/10.1053/j.gastro.2005.01.048] [PMID: 15825070]
[34]
Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132(1): 52-65.
[http://dx.doi.org/10.1053/j.gastro.2006.11.041] [PMID: 17241859]
[35]
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357(3): 239-50.
[http://dx.doi.org/10.1056/NEJMoa062897] [PMID: 17634459]
[36]
Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357(3): 228-38.
[http://dx.doi.org/10.1056/NEJMoa067594] [PMID: 17634458]
[37]
Schreiber S, Lawrance IC, Thomsen OØ, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011; 33(2): 185-93.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04509.x] [PMID: 21083671]
[38]
Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 2013; 11(8): 975-81. .e1, 4.
[http://dx.doi.org/10.1016/j.cgh.2012.12.042] [PMID: 23376316]
[39]
Colombel J-F, Feagan BG, Sandborn WJ, Van Assche G, Robinson AM. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis 2012; 18(2): 349-58.
[http://dx.doi.org/10.1002/ibd.21831] [PMID: 22021134]
[40]
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369(8): 711-21.
[http://dx.doi.org/10.1056/NEJMoa1215739] [PMID: 23964933]
[41]
Feagan B, Schwartz D, Danese S, et al. Vedolizumab for the treatment of fistulising Crohn’s disease: An exploratory analysis of data from GEMINI 2. J Crohn’s Colitis 2015; 9: S333-4.
[http://dx.doi.org/10.1093/ecco-jcc/jju027.626]
[42]
Sands BE, Blank MA, Diamond RH, Barrett JP, Van Deventer SJ. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn’s disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006; 23(8): 1127-36.
[http://dx.doi.org/10.1111/j.1365-2036.2006.02878.x] [PMID: 16611273]
[43]
Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the Treatment of Refractory Crohnʼs Disease. Inflamm Bowel Dis 2016; 22(7): 1662-9.
[http://dx.doi.org/10.1097/MIB.0000000000000842] [PMID: 27306072]
[44]
Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther 2017; 45(9): 1232-43.
[http://dx.doi.org/10.1111/apt.14016] [PMID: 28252210]
[45]
Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337(15): 1029-35.
[http://dx.doi.org/10.1056/NEJM199710093371502] [PMID: 9321530]
[46]
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359(9317): 1541-9.
[http://dx.doi.org/10.1016/S0140-6736(02)08512-4] [PMID: 12047962]
[47]
Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 2005; 129(3): 807-18.
[http://dx.doi.org/10.1053/j.gastro.2005.06.064] [PMID: 16143120]
[48]
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2): 323-33.
[http://dx.doi.org/10.1053/j.gastro.2005.11.030] [PMID: 16472588]
[49]
Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56(9): 1232-9.
[http://dx.doi.org/10.1136/gut.2006.106781] [PMID: 17299059]
[50]
Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132(1): 52-65.
[http://dx.doi.org/10.1053/j.gastro.2006.11.041] [PMID: 17241859]
[51]
Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146(12): 829-38.
[http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00159] [PMID: 17470824]
[52]
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010; 362(15): 1383-95.
[http://dx.doi.org/10.1056/NEJMoa0904492] [PMID: 20393175]
[53]
Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9(8): 670-678.e3.
[http://dx.doi.org/10.1016/j.cgh.2011.04.031] [PMID: 21642014]
[54]
Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF therapy in Crohn’s disease. Int J Mol Sci 2018; 19(8): E2244.
[http://dx.doi.org/10.3390/ijms19082244] [PMID: 30065229]
[55]
Graf W, Andersson M, Åkerlund J-E, Börjesson L. Long-term outcome after surgery for Crohn’s anal fistula. Colorectal Dis 2016; 18(1): 80-5.
[http://dx.doi.org/10.1111/codi.13106] [PMID: 26338142]
[56]
Adegbola SO, Sahnan K, Pellino G, et al. Short-term efficacy and safety of three novel sphincter-sparing techniques for anal fistulae: a systematic review. Tech Coloproctol 2017; 21(10): 775-82.
[http://dx.doi.org/10.1007/s10151-017-1699-4] [PMID: 29080959]
[57]
Wong S, Solomon M, Crowe P, Ooi K. Cure, continence and quality of life after treatment for fistula-in-ano. ANZ J Surg 2008; 78(8): 675-82.
[http://dx.doi.org/10.1111/j.1445-2197.2008.04616.x] [PMID: 18796027]
[58]
Sahnan K, Tozer PJ, Adegbola SO, et al. Developing a core outcome set for fistulising perianal Crohn’s disease. Gut 2019; 68(2): 226-38.
[http://dx.doi.org/10.1093/ecco-jcc/jjx180.103]
[59]
Cirocchi R, Farinella E, La Mura F, et al. Fibrin glue in the treatment of anal fistula: a systematic review. Ann Surg Innov Res 2009; 3(1): 12.
[http://dx.doi.org/10.1186/1750-1164-3-12] [PMID: 19912660]
[60]
Senéjoux A, Siproudhis L, Abramowitz L, et al. Fistula plug in fistulising ano-perineal Crohn’s Disease: A randomised controlled trial. J Crohn’s Colitis 2016; 10(2): 141-8.
[http://dx.doi.org/10.1093/ecco-jcc/jjv162] [PMID: 26351393]
[61]
Datta I, Johnston C, Baxter NN. A systematic review of the anal fistula plug for patients with crohnʼs and non-crohnʼs related fistula-in-ano. Dis Colon Rectum 2012; 55(3): 351-8.
[http://dx.doi.org/10.1097/DCR.0b013e318239d1e4] [PMID: 22469804]
[62]
Taxonera C, Schwartz DA, García-Olmo D. Emerging treatments for complex perianal fistula in Crohn’s disease. World J Gastroenterol 2009; 15(34): 4263-72.
[http://dx.doi.org/10.3748/wjg.15.4263] [PMID: 19750568]
[63]
Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum 2010; 53(4): 486-95.
[http://dx.doi.org/10.1007/DCR.0b013e3181ce8b01] [PMID: 20305451]
[64]
Ky AJ, Sylla P, Steinhagen R, et al. Collagen fistula plug for the treatment of anal fistulas. Dis Colon Rectum 2008; 51(6): 838-43.
[http://dx.doi.org/10.1007/s10350-007-9191-2] [PMID: 18330649]
[65]
Dietz AB, Dozois EJ, Fletcher JG, et al. Autologous mesenchymal stem cells, applied in a bioabsorbable matrix, for treatment of perianal fistulas in patients with Crohn’s Disease. Gastroenterology 2017; 153(1): 59-62.e2.
[http://dx.doi.org/10.1053/j.gastro.2017.04.001] [PMID: 28400193]
[66]
Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52(1): 79-86.
[http://dx.doi.org/10.1007/DCR.0b013e3181973487] [PMID: 19273960]
[67]
Pellino G, Selvaggi F. Surgical treatment of perianal fistulizing Crohn’s disease: From lay-open to cell-based therapy--an overview. Sci World J 2014; 2014: 146281.
[http://dx.doi.org/10.1155/2014/146281] [PMID: 25431776]
[68]
Mizrahi N, Wexner SD, Zmora O, et al. Endorectal advancement flap: are there predictors of failure? Dis Colon Rectum 2002; 45(12): 1616-21.
[http://dx.doi.org/10.1007/s10350-004-7248-z] [PMID: 12473884]
[69]
Göttgens KWA, Smeets RR, Stassen LPS, et al. Treatment of Crohn’s disease-related high perianal fistulas combining the mucosa advancement flap with platelet-rich plasma: a pilot study. Tech Coloproctol 2015; 19(8): 455-9.
[http://dx.doi.org/10.1007/s10151-015-1311-8] [PMID: 25975971]
[70]
Soltani A, Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum 2010; 53(4): 486-95.
[http://dx.doi.org/10.1007/DCR.0b013e3181ce8b01] [PMID: 20305451]
[71]
Gingold DS. Murrell Z a, Fleshner PR. A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with crohn disease. Ann Surg 2013; 00(00): 1-5.
[http://dx.doi.org/10.1097/SLA.0000000000000479] [PMID: 24374520]
[72]
Kamiński JP, Zaghiyan K, Fleshner P. Increasing experience of LIFT procedure for patients with Crohn’s disease: what have we learned?. Color Dis 2017.
[http://dx.doi.org/10.1111/codi.13668]
[73]
Lee WY, Park KJ, Cho YB, et al. Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn’s fistula. Stem Cells 2013; 31(11): 2575-81.
[http://dx.doi.org/10.1002/stem.1357] [PMID: 23404825]
[74]
Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 2011; 60(6): 788-98.
[http://dx.doi.org/10.1136/gut.2010.214841] [PMID: 21257987]
[75]
de la Portilla F, Alba F, García-Olmo D, Herrerías JM, González FX, Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013; 28(3): 313-23.
[http://dx.doi.org/10.1007/s00384-012-1581-9] [PMID: 23053677]
[76]
Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology 2015; 149(4): 918-27.e6.
[http://dx.doi.org/10.1053/j.gastro.2015.06.014] [PMID: 26116801]
[77]
García-Olmo D, García-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48(7): 1416-23.
[http://dx.doi.org/10.1007/s10350-005-0052-6] [PMID: 15933795]
[78]
Cho YB, Lee WY, Park KJ, et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn’s fistula: A phase I clinical study. Cell Transplant 2013; 22(2): 279-85.
[http://dx.doi.org/10.3727/096368912X656045] [PMID: 23006344]
[79]
Panés J, García-Olmo D, Van Assche G, et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 2016; 388(10051): 1281-90.
[http://dx.doi.org/10.1016/S0140-6736(16)31203-X] [PMID: 27477896]
[80]
Gu J, Valente MA, Remzi FH, Stocchi L. Factors affecting the fate of faecal diversion in patients with perianal Crohn’s disease. Colorectal Dis 2015; 17(1): 66-72.
[http://dx.doi.org/10.1111/codi.12796] [PMID: 25306934]
[81]
Kasparek MS, Glatzle J, Temeltcheva T, et al. Long-term quality of life in patients with Crohn’s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum 2007; 50(12): 2067-74.
[http://dx.doi.org/10.1007/s10350-007-9006-5] [PMID: 17680311]
[82]
Yamamoto T, Bain IM, Allan RN, Keighley MR. Persistent perineal sinus after proctocolectomy for Crohn’s disease. Dis Colon Rectum 1999; 42(1): 96-101.
[http://dx.doi.org/10.1007/BF02235190] [PMID: 10211527]
[83]
Lewis RT, Maron DJ. Efficacy and complications of surgery for Crohn’s disease. Gastroenterol Hepatol (N Y) 2010; 6(9): 587-96.
[PMID: 21088749]
[84]
Bermejo F, Guerra I, Algaba A, López-Sanromán A. Pharmacological approach to the management of crohn’s disease patients with perianal disease. Drugs 2018; 78(1): 1-18.
[http://dx.doi.org/10.1007/s40265-017-0842-x] [PMID: 29139091]
[85]
Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol 2014; 7: 359-67.
[http://dx.doi.org/10.2147/CEG.S45297] [PMID: 25258548]
[86]
Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther 2017; 45(7): 933-40.
[http://dx.doi.org/10.1111/apt.13970] [PMID: 28211593]
[87]
Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s Disease. J Crohn’s Colitis 2017; 11(5): 549-55.
[http://dx.doi.org/10.1093/ecco-jcc/jjw182] [PMID: 28453755]
[88]
Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn’s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9(2): 98-103.
[http://dx.doi.org/10.1097/00054725-200303000-00003] [PMID: 12769443]
[89]
Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease Guidance and guidelines NICE.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy